Inozyme Pharma, Inc. Price & Performance (INZY)

Inozyme Pharma's stock has hit a 52-week low of $0.98, reflecting an 83% drop over the past year. The company faces market pressures and clinical challenges, though analysts maintain price targets up to $23. Despite the downturn, Inozyme's liquidity remains strong, and its rare disease pipeline continues to show promise.12

Research analysts have reduced price targets for Inozyme Pharma following its stock's sharp decline. Piper Sandler adjusted its target to $23, while Needham cut its estimate to $15. Despite the bearish outlook, analysts highlight the potential of INZ-701, an investigational drug targeting rare diseases, as a key growth opportunity.34

Inozyme Pharma's market cap has fallen to $64 million, with shares trading at $1.00. Institutional investors have reduced stakes, while analysts debate the stock's future. With a strong cash position and ongoing trial results, the company is navigating volatility in the biotech sector.56